SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001013762-23-006986
Filing Date
2023-10-26
Accepted
2023-10-26 17:00:50
Documents
2
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL MASTER FUND, L.P.SOLEUS CAPITAL, LLCSOLEUS PE GP III, LLCSOLEUS PRIVATE EQUITY GP III, LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G ea187336-13gsoleus3_harpoon.htm SC 13G 127239
2 JOINT FILING AGREEMENT ea187336ex99-1_harpoon.htm EX-99.1 13585
  Complete submission text file 0001013762-23-006986.txt   142596
Mailing Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 400 SOUTH SAN FRANCISCO CA 94080 (650) 443-7400
Harpoon Therapeutics, Inc. (Subject) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-90935 | Film No.: 231350892
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830 475-208-3178
Soleus Private Equity Fund III, L.P. (Filed by) CIK: 0001955982 (see all company filings)

IRS No.: 880637097 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G